Sandhya Ravishankar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sandhya Ravishankar has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Bhavya Ekambaram
Department of Pharmacy Practice, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences,Thandalam, Chennai, Tamil Nadu, India
2 shared publications - Nisha Boopathi
Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences (SIMATS)—Deemed to be University, Chennai, Tamil Nadu, India
2 shared publications - Rajagopal Sakthivel Sharanitha
Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences (SIMATS)—Deemed to be University, Chennai, Tamil Nadu, India
2 shared publications Akshaya Murugathirumal
Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences (SIMATS)—Deemed to be University, Chennai, Tamil Nadu, India
1 shared publication- Christan M
Research Scholar, Department of Pharmacy Practice, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences, (Deemed to be University), Saveetha Nagar, Chennai 602125, India
1 shared publication - Jayasri Bantaram
Department of Pharmaceutics, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences, Chennai, India
1 shared publication
Latest Publications
- Open Access
- 21 May 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 01_Special (19) , 994
BiP/GRP78 and Unfolded Protein Response in Parkinson’s Disease: Mechanisms, Therapeutic Potential, and Future Directions
Parkinson’s disease (PD) is a progressive neurodegenerative illness characterized by the buildup of misfolded alpha-synuclein in Lewy bodies and the loss of dopaminergic neurons in the substantia nigra. The unfolded protein response (UPR) and endoplasmic reticulum (ER) stress have been implicated in the pathophysiology of Parkinson’s disease (PD) in recent research.BiP/GRP78, an ER-resident chaperone, serves as a central regulator of the UPR by sensing misfolded proteins and modulating three primary stress sensors: PERK, IRE1, and ATF6. While BiP initially acts protectively by restoring ER homeostasis, its sustained activation may lead to maladaptive UPR signaling and neuronal apoptosis. Experimental models have demonstrated that agents such as salubrinal can modulate BiP levels and UPR activity, offering neuroprotection. Moreover, small molecules targeting BiP interactions or its ATPase activity are emerging as potential therapeutics. However, challenges such as blood–brain barrier penetration, tissue-specific effects, and long-term safety must be addressed. Future strategies may include targeted delivery systems, combination therapies involving autophagy modulation, and personalized treatment guided by BiP expression or genomic profiling. This review outlines the dual role of BiP in PD and discusses its therapeutic implications, highlighting the need for precise modulation to maximize clinical benefits while minimizing risks.
- 21 May 2026
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 01_Special (19) , 994
Open AccessBiP/GRP78 and Unfolded Protein Response in Parkinson’s Disease: Mechanisms, Therapeutic Potential, and Future Directions
Parkinson’s disease (PD) is a progressive neurodegenerative illness characterized by the buildup of misfolded alpha-synuclein in Lewy bodies and the loss of dopaminergic neurons in the substantia nigra. The unfolded protein response (UPR) and endoplasmic reticulum (ER) stress have been implicated in the pathophysiology of Parkinson’s disease (PD) in recent research.BiP/GRP78, an ER-resident chaperone, serves as a central regulator of the UPR by sensing misfolded proteins and modulating three primary stress sensors: PERK, IRE1, and ATF6. While BiP initially acts protectively by restoring ER homeostasis, its sustained activation may lead to maladaptive UPR signaling and neuronal apoptosis. Experimental models have demonstrated that agents such as salubrinal can modulate BiP levels and UPR activity, offering neuroprotection. Moreover, small molecules targeting BiP interactions or its ATPase activity are emerging as potential therapeutics. However, challenges such as blood–brain barrier penetration, tissue-specific effects, and long-term safety must be addressed. Future strategies may include targeted delivery systems, combination therapies involving autophagy modulation, and personalized treatment guided by BiP expression or genomic profiling. This review outlines the dual role of BiP in PD and discusses its therapeutic implications, highlighting the need for precise modulation to maximize clinical benefits while minimizing risks.
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Journal of Bio-X Research
- Vol. 9
mRNA-Based Nanomedicine in Cancer: Pharmacokinetic Innovations, Clinical Pharmacy Practice Integration, and the Future of Personalized Oncology
As a revolutionary breakthrough in cancer treatment, messenger RNA (mRNA)-based nanomedicine provides a versatile and programmable platform to elicit strong antitumor responses. In contrast to conventional treatments, mRNA can encode therapeutic proteins, immune activators, or tumor antigens, allowing for highly individualized treatment plans. However, efficient delivery is still a major problem that has been solved by the creation of nanocarriers such as lipid nanoparticles, polymeric vectors, and exosome mimics. These systems reduce off-target effects while improving stability, cellular uptake, and tumor targeting. With an emphasis on delivery methods, clinical pharmacokinetics, tumor penetration, metabolism, and immune pharmacodynamics, this review offers a thorough summary of mRNA nanomedicine in oncology. The safety profiles and efficacy signals of important clinical trials, including Moderna’s mRNA-4359 for NSCLC treatment and BNT111 for melanoma treatment, have been analyzed. Practical considerations for real-world integration, such as the preparation, monitoring, and patient education responsibilities of pharmacists and oncologists, are also covered. Clinical decision-making is supported by the use of visual aids such as radar charts and comparative summary tables, which help to simplify complex datasets. The development of adherence support tools for pharmaceutical practice, artificial intelligence-driven immune response prediction, and customized mRNA design are highlighted as future directions. Success in the journey of mRNA nanomedicine from bench to bedside will rely on interdisciplinary cooperation, strong regulatory frameworks, and medical staff prepared to handle these cutting-edge treatments. The purpose of this article is to help physicians, researchers, and pharmacy professionals navigate the rapidly changing field of mRNA therapeutics in oncology.
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Journal of Bio-X Research
- Vol. 9
mRNA-Based Nanomedicine in Cancer: Pharmacokinetic Innovations, Clinical Pharmacy Practice Integration, and the Future of Personalized Oncology
As a revolutionary breakthrough in cancer treatment, messenger RNA (mRNA)-based nanomedicine provides a versatile and programmable platform to elicit strong antitumor responses. In contrast to conventional treatments, mRNA can encode therapeutic proteins, immune activators, or tumor antigens, allowing for highly individualized treatment plans. However, efficient delivery is still a major problem that has been solved by the creation of nanocarriers such as lipid nanoparticles, polymeric vectors, and exosome mimics. These systems reduce off-target effects while improving stability, cellular uptake, and tumor targeting. With an emphasis on delivery methods, clinical pharmacokinetics, tumor penetration, metabolism, and immune pharmacodynamics, this review offers a thorough summary of mRNA nanomedicine in oncology. The safety profiles and efficacy signals of important clinical trials, including Moderna’s mRNA-4359 for NSCLC treatment and BNT111 for melanoma treatment, have been analyzed. Practical considerations for real-world integration, such as the preparation, monitoring, and patient education responsibilities of pharmacists and oncologists, are also covered. Clinical decision-making is supported by the use of visual aids such as radar charts and comparative summary tables, which help to simplify complex datasets. The development of adherence support tools for pharmaceutical practice, artificial intelligence-driven immune response prediction, and customized mRNA design are highlighted as future directions. Success in the journey of mRNA nanomedicine from bench to bedside will rely on interdisciplinary cooperation, strong regulatory frameworks, and medical staff prepared to handle these cutting-edge treatments. The purpose of this article is to help physicians, researchers, and pharmacy professionals navigate the rapidly changing field of mRNA therapeutics in oncology.
- 5 December 2025
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 257, 106908
Tryptophan-steroid interactions in the brain–gut–microbiome axis: Neuroactive metabolites as biomarkers and therapeutic targets
- 5 December 2025
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 257, 106908
Tryptophan-steroid interactions in the brain–gut–microbiome axis: Neuroactive metabolites as biomarkers and therapeutic targets